Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation

被引：0

作者：

Zhu, Jinlian ^{[1
]}

Chen, Jie ^{[1
]}

Liu, Wei ^{[1
]}

Zhang, Junling ^{[2
]}

Gu, Yulan ^{[1
]}

机构：

[1] Nantong Univ, Dept Otolaryngol, Affiliated Changshu Hosp, Changshu, Jiangsu, Peoples R China

[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China

来源：

LUNG CANCER-TARGETS AND THERAPY | 2024年 / 15卷

关键词：

MET Y1003H; MET D1228N; crizotinib; resistance; NSCLC; LUNG; CABOZANTINIB; SENSITIVITY; INHIBITORS; PATIENT; DOMAIN; SITE;

D O I：

10.2147/LCTT.S467584

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mesenchymal-epithelial transition (MET) gene has been identified as a promising target for treatments. However, different sites of the MET mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring MET Y1003H mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of MET D1228N as a possible mechanism of acquired resistance to crizotinib in a patient with MET Y1003H mutation during disease progression.

引用

页码：123 / 128

页数：6

共 36 条

[11] CapmatinibAcquired MET D1228H mutation: case report
Reactions Weekly, 2024, 2026 (1) : 73 - 73
[12] Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib Response
Radonic, Teodora
Geurts-Giele, Willemina R. R.
Dubbink, Hendrikus Jan
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : E56 - E56
[13] Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Bahcall, Magda
Sim, Taebo
Paweletz, Cloud P.
Patel, Jyoti D.
Alden, Ryan S.
Kuang, Yanan
Sacher, Adrian G.
Kim, Nam Doo
Lydon, Christine A.
Awad, Mark M.
Jaklitsch, Michael T.
Sholl, Lynette M.
Jaenne, Pasi A.
Oxnard, Geoffrey R.
CANCER DISCOVERY, 2016, 6 (12) : 1334 - 1341
[14] Switching inhibitor class overcomes crizotinib resistance in a MET fusion-positive NSCLC with a novel acquired MET G1090A mutation
Murciano-Goroff, Yonina R.
Kannan, Srinivasaraghavan
Chang, Jason C.
Benayed, Ryma
Blokhin, Ilya
Rekhtman, Natasha
Sisk, Ann Elizabeth
Gibson, Jaime
Judka, Lia
Kaplanis, Lauren
Merrill, Madeline
Sgroe, Erica
Verma, Chandra S.
Drilon, Alexander
Cocco, Emiliano
CANCER RESEARCH, 2022, 82 (12)
[15] MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma
Miao, Yun L.
Xu, Qing Qing
LUNG CANCER, 2019, 130 : 84 - 86
[16] Cabozantinib/crizotinibDe novo acquisition of MET D1228N mutation in MET-amplified triple-negative breast cancer and progression of disease with various toxicities
Reactions Weekly, 2022, 1887 (1) : 164 - 164
[17] A rapid and durable response to cabozantinib in an osimertinib- resistant lung cancer patient with MET D1228N mutation: a case report
Kuang, Yukun
Wang, Jiyu
Xu, Peihang
Zheng, Yifan
Bai, Lihong
Sun, Xue
Li, Zimu
Gan, Runjing
Li, Huixia
Ke, Zunfu
Tang, Kejing
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
[18] A Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient with Acquired MET Amplification
Liang, Y.
Chen, Q.
Lin, Y.
Liu, H.
Qiu, B.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S890 - S890
[19] Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion
Dong, Su-Su
Dong, Wen
Tan, Ya-Fen
Xiao, Qiang
Wang, Tian-Li
FRONTIERS IN ONCOLOGY, 2024, 14
[20] Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
Umeda, Yukihiro
Kimura, Satomi
Kimura, Junya
Imamura, Yoshiaki
Ishizuka, Tamotsu
THORACIC CANCER, 2025, 16 (02)

← 1 2 3 4 →